The Securities and Exchange Commission announced the temporary suspension, pursuant to Section 12(k) of the Securities Exchange Act of 1934, of trading in the securities of Immune Pharmaceuticals Inc. (“IMNPQ” or “the Company”) (CIK No. 0001208261), of Fort Lee, New Jersey at 9:30 a.m. EDT on April 19, 2021, and terminating at 11:59 p.m. EDT on April 30, 2021.

The Commission temporarily suspended trading in the securities of IMNPQ because there is a lack of current and accurate information concerning the securities of IMNPQ because it is delinquent in its periodic filings with the Commission, having not filed any periodic reports since it filed a Form 10-Q for the period ending September 30, 2018, and because of questions regarding the accuracy of publicly available information in the marketplace concerning IMNPQ, including current reports on Form 8-K filed on April 12, 2021 and April 13, 2021; the Company’s assets; the Company’s current financial condition; and recent, increased trading activity in the securities of IMNPQ despite its status as a debtor in a Chapter 7 bankruptcy proceeding.

The Commission cautions broker-dealers, shareholders, and prospective purchasers that they should carefully consider the foregoing information along with all other currently available information and any information subsequently issued by the company.

Further, brokers and dealers should be alert to the fact that, pursuant to Rule 15c2-11 under the Exchange Act, at the termination of the trading suspension, no quotation may be entered unless and until they have strictly complied with all of the provisions of the rule. If any broker or dealer has any questions as to whether or not it has complied with the rule, it should not enter any quotation but immediately contact the staff in the Division of Trading and Markets, Office of Interpretation and Guidance, at (202) 551-5777. If any broker or dealer is uncertain as to what is required by Rule 15c2-11, it should refrain from entering quotations relating to IMNPQ’s securities until such time as it has familiarized itself with the rule and is certain that all of its provisions have been met. If any broker or dealer enters any quotation which is in violation of the rule, the Commission will consider the need for prompt enforcement action.

If any broker-dealer or other person has any information that may relate to this matter, they should immediately contact Thomas P. Smith, Jr., Assistant Regional Director, at (212) 336-0171.